Cargando…

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria

BACKGROUND: Although changes in the tyrosine pathway during nitisinone therapy are known, a complete characterization of the induced tyrosinaemia is lacking to improve disease management. PATIENTS AND METHODS: Our research aims were addressed by 24-h blood sampling. 40 patients with alkaptonuria (AK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranganath, L.R., Milan, A.M., Hughes, A.T., Davison, A.S., Khedr, M., Norman, B.P., Bou-Gharios, G., Gallagher, J.A., Gornall, M., Jackson, R., Imrich, R., Rovensky, J., Rudebeck, M., Olsson, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856922/ https://www.ncbi.nlm.nih.gov/pubmed/35242577 http://dx.doi.org/10.1016/j.ymgmr.2022.100846

Ejemplares similares

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
por: Milan, A. M., et al.
Publicado: (2019)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2021)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
por: Norman, Brendan P., et al.
Publicado: (2022)

Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2020)

Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria
por: Davison, Andrew S., et al.
Publicado: (2022)

Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?
por: Davison, A.S., et al.
Publicado: (2020)

Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, A. S., et al.
Publicado: (2019)

Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone
por: Griffin, R., et al.
Publicado: (2018)

Correction to: Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, Andrew S., et al.
Publicado: (2019)

Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
por: Davison, Andrew S., et al.
Publicado: (2019)

Increased prevalence of Parkinson's disease in alkaptonuria
por: Ranganath, Lakshminarayan, et al.
Publicado: (2023)

Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
por: Ooi, Nicola, et al.
Publicado: (2023)

Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature
por: Ranganath, Lakshminarayan, et al.
Publicado: (2021)

First decade anniversary of the United Kingdom National Alkaptonuria Centre
por: Khedr, Milad, et al.
Publicado: (2023)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Effects of a protein‐restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria
por: Olsson, Birgitta, et al.
Publicado: (2021)

Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies
por: Braconi, Daniela, et al.
Publicado: (2022)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients
por: Ahmad, Mohammad S. Z., et al.
Publicado: (2022)

Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism
por: Norman, Brendan P., et al.
Publicado: (2021)

Long‐term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression
por: Davison, Andrew S., et al.
Publicado: (2022)

Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate – A report of two cases
por: Ranganath, L.R., et al.
Publicado: (2021)

Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design
por: Psarelli, Eftychia Eirini, et al.
Publicado: (2013)

Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index
por: Cant, Harriet E. O., et al.
Publicado: (2022)

A case report of pregnancy in untreated alkaptonuria – Focus on urinary tissue remodelling markers
por: Ranganath, L.R., et al.
Publicado: (2021)

Analysis of the Phenotype Differences in Siblings with Alkaptonuria
por: Zatkova, Andrea, et al.
Publicado: (2022)

The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma
por: Judd, Shirley, et al.
Publicado: (2020)

Development of an Effective Therapy for Alkaptonuria – Lessons for Osteoarthritis
por: Gallagher, James A., et al.
Publicado: (2021)

A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care
por: Rudebeck, Mattias, et al.
Publicado: (2020)

Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria
por: Hughes, Juliette H, et al.
Publicado: (2019)

Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2‐dioxygenase deficiency in the liver is responsible for homogentisic acid‐derived ochronotic pigmentation
por: Wilson, Peter J. M., et al.
Publicado: (2020)

Alkaptonuria: Current Perspectives
por: Zatkova, Andrea, et al.
Publicado: (2020)

Pigmentation Chemistry and Radical‐Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage
por: Chow, Wing Ying, et al.
Publicado: (2020)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nfo90lsuik48k45p8a5jsiujr5